REmote Virtual Inspiration: Vitality and Energy (REVIVE)
Improving Cardiometabolic Health With Meditative Movement in Mobility Impaired Women
REVIVE is a randomized controlled trial designed to evaluate the effects of a remotely delivered seated Tai Chi/Qigong (TCQ) intervention on cardiometabolic health, stress, sleep, and psychological well-being among women with mobility impairments.
Women with mobility impairments experience higher rates of obesity, cardiometabolic disease, chronic stress, sleep disturbances, and mental health concerns compared with women without disabilities. Limited access to accessible physical activity programs and barriers to participation in traditional exercise interventions contribute to these health disparities. Tai Chi and Qigong are gentle mind-body practices that may improve physical and psychological health through movement, breathing, and mindfulness techniques and can be adapted for individuals with limited mobility.
Participants will be randomized to either a seated Tai Chi/Qigong intervention or a health education video control condition. During the 12-week intervention phase, participants will receive daily video-based content delivered remotely. Participants assigned to the Tai Chi/Qigong group will engage in seated meditative movement practices, while participants assigned to the control group will receive health and wellness education videos unrelated to physical activity or nutrition behavior change.
Outcomes will be assessed remotely at baseline, post-intervention, and follow-up. Primary outcomes include waist circumference and indicators of physiological stress regulation, including heart rate variability and salivary cortisol. Secondary outcomes include perceived stress, emotion regulation, depression, anxiety, emotional eating, sleep quality, and sleep disturbance. Additional measures collected through wearable technology, sleep diaries, questionnaires, and biological samples will be used to examine potential behavioral, psychological, and physiological mechanisms underlying intervention effects.
The findings from this study will contribute to the development of accessible, scalable, and evidence-based health promotion interventions designed to improve cardiometabolic health and overall well-being among women with mobility impairments.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
The REVIVE study is a fully remote, two-arm randomized controlled trial designed to test a seated Tai Chi/Qigong intervention adapted for women with mobility impairments. The study addresses the need for accessible, home-based interventions that can support health and well-being among individuals who may experience barriers to traditional in-person physical activity programs.
Participants complete all study activities from home over approximately 30 weeks. After screening and baseline procedures, participants are randomized to one of two study conditions: a seated Tai Chi/Qigong intervention or a health education video control condition. The study includes a baseline assessment period, a 12-week guided intervention phase, a post-intervention assessment period, a 12-week unprompted phase, and a final follow-up assessment period.
During the guided intervention phase, participants receive daily video-based content. Participants assigned to the Tai Chi/Qigong condition receive seated practice videos that include gentle movements, breathing exercises, mindfulness, relaxation, body awareness, and meditative movement practices. Videos include shorter and longer options to support flexibility and accommodate participant preferences, and schedules.
Participants assigned to the health education video control condition receive daily wellness education videos delivered with the same frequency and format. Control videos address general wellness topics but do not include meditative movement, structured exercise instruction, or physical activity behavior change strategies.
Study assessments are conducted remotely using online surveys, wearable technology, sleep diaries, remote measurement procedures, and at-home saliva collection. Study staff provide training and online support to help participants complete study activities and assessments from home.
REVIVE will evaluate whether a remotely delivered, seated Tai Chi/Qigong intervention adapted for women with mobility impairments can improve cardiometabolic and stress-related health outcomes. The study will also examine potential biological, psychological, and behavioral pathways that may explain intervention effects. Findings may inform future clinical and community-based programs designed to improve health and quality of life among women with mobility impairments.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Rebecca E Lee, PhD
- Número de telefone: 6024960910
- E-mail: releephd@yahoo.com
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85004
- Recrutamento
- Arizona State University
-
Contato:
- Rebecca E Lee, PhD
- Número de telefone: 6024960910
- E-mail: releephd@yahoo.com
-
Investigador principal:
- Rebecca E Lee, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Self-identify as a woman.
- Age 35-64 years.
- Mobility impairment lasting at least 1 year.
- Regular use of a mobility aid (e.g., wheelchair, scooter, walker, cane, crutches, or other assistive device).
- Community dwelling.
- Able to demonstrate sufficient upper-extremity mobility to participate in seated Tai Chi/Qigong activities.
- Access to a smartphone, tablet, or computer with internet access.
- Willing to wear a study-provided wearable device and complete study assessments.
- Reside in the United States.
- Waist circumference ≥ 33 inches (84 cm).
- Perceived Stress Scale (PSS) score ≥ 15.
- Insomnia Severity Index (ISI) score ≥ 8.
- Emotional eating indicated by a score < 3 on the Mindful Eating Questionnaire (MEQ) Emotional Response subscale.
- Able to understand written and spoken English.
- Able to provide informed consent.
- Able to provide healthcare provider approval for participation.
Exclusion Criteria:
- Medical conditions that would make participation unsafe, as determined during screening.
- Inability to safely perform seated upper-body movements.
- Current participation in a structured Tai Chi, Qigong, or similar meditative movement program.
- Pregnancy, lactation, or plans to become pregnant during the study period.
- Cognitive, visual, auditory, or other impairments that would preclude completion of study procedures.
- Implanted cardiac devices or implanted electronic devices that interfere with physiologic measurements.
- Severe arrhythmia, left ventricular assist device (LVAD), or other conditions that interfere with heart rate variability assessment.
- Use of sleep medications three or more times per week.
- Medical conditions or medications that substantially affect autonomic nervous system activity, sleep, or stress-related outcomes.
- Uncontrolled cardiovascular, neurological, psychiatric, or other serious medical conditions that would preclude safe participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Accesible Tai Chi/Qigong
Participants receive a 12-week remotely delivered seated Tai Chi/Qigong intervention consisting of daily video-based meditative movement sessions adapted for women with mobility impairments.
|
A remotely delivered seated Tai Chi/Qigong intervention designed for women with mobility impairments.
Participants receive daily video-based sessions that incorporate seated meditative movement, breathing exercises, mindfulness, relaxation techniques, and body awareness practices.
Short and long session options are available throughout the 12-week intervention period.
|
|
Comparador Ativo: Health Education Videos (HEV)
Participants receive a 12-week remotely delivered health education program consisting of daily video-based wellness education content on a variety of health-related topics.
|
A remotely delivered health education program consisting of daily video-based wellness education content provided over 12 weeks.
Topics include healthy aging, preventive healthcare, chronic disease awareness, communication with healthcare providers, and other general wellness topics.
The program does not include Tai Chi, Qigong, exercise instruction, or physical activity behavior change content.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Waist Circumference (cm)
Prazo: Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
|
Change in waist circumference measured in centimeters using a standardized Zoom-guided measurement protocol.
Waist circumference is used as an indicator of abdominal adiposity and cardiometabolic risk.
|
Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
|
|
High-Frequency Heart Rate Variability (HF Power)
Prazo: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
Change in nocturnal high-frequency (HF) heart rate variability power measured using the Oura Ring.
Higher HF power indicates greater parasympathetic nervous system activity and autonomic balance.
HF power is the primary heart rate variability parameter used to assess physiological stress regulation.
|
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
|
Diurnal Salivary Cortisol Area Under the Curve (AUCg)
Prazo: Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
|
Change in diurnal salivary cortisol area under the curve with respect to ground (AUCg), calculated from saliva samples collected over two days with three samples per day.
Lower AUCg values indicate reduced hypothalamic-pituitary-adrenal (HPA) axis activation and biological stress.
|
Baseline (T1), Post-Intervention (T2, Week 15), and Follow-Up (T3, Week 29)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Perceived Stress Scale (PSS-10) Total Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in perceived stress measured using the 10-item Perceived Stress Scale (PSS-10).
Scores range from 0 to 40, with higher scores indicating greater perceived stress.
The primary reported value will be the total score.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Emotion Regulation Questionnaire (ERQ) Cognitive Reappraisal Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in cognitive reappraisal measured using the Emotion Regulation Questionnaire (ERQ).
Scores range from 1 to 7, with higher scores indicating greater use of cognitive reappraisal strategies.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Center for Epidemiologic Studies Depression Scale (CES-D-10) Total Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in depressive symptoms measured using the 10-item CES-D.
Scores range from 0 to 30, with higher scores indicating greater depressive symptom severity.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Generalized Anxiety Disorder-7 (GAD-7) Total Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in anxiety symptoms measured using the Generalized Anxiety Disorder-7 (GAD-7).
Scores range from 0 to 21, with higher scores indicating greater anxiety severity.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Insomnia Severity Index (ISI) Total Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in insomnia symptoms measured by the Insomnia Severity Index (ISI).
The ISI is a 7-item self-report questionnaire with total scores ranging from 0 to 28.
Higher scores indicate greater insomnia severity.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Sleep Efficiency Measured by Oura Ring
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in sleep efficiency (%) measured objectively using the Oura Ring wearable device.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Sleep Diary
Prazo: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
Average sleep outcomes derived from the 14-day Consensus Sleep Diary completed during each assessment period.
|
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
|
Mindful Eating Questionnaire (MEQ) Emotional Eating Subscale Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in emotional eating measured using the Emotional Eating subscale of the Mindful Eating Questionnaire (MEQ).
Subscale scores range from 1 to 4, with higher scores indicating lower levels of emotional eating and more mindful eating behaviors.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
PROMIS Sleep Disturbance Short Form T-Score
Prazo: Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
Change in sleep disturbance measured using the PROMIS Sleep Disturbance Short Form.
Raw scores range from 8 to 40 and are converted to standardized T-scores, with higher T-scores indicating greater sleep disturbance.
|
Baseline (T1), Week 15 (T2; post-intervention), and Week 29 (T3; follow-up)
|
|
Check And Line Questionnaire (CALQ)
Prazo: Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
Average daily minutes of self-reported physical activity will be measured using the Check and Line Questionnaire (CALQ) over the 14-day assessment period.
Participants will report total daily or weekly minutes of light, moderate, and vigorous physical activity, or any combination of these, rounded to the nearest 15-minute increment.
|
Baseline 2-week assessment period, Week 15 (post-intervention) 2-week assessment period, and Week 29 (follow-up) 2-week assessment period.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- STUDY00023587
- R01AG088032-01A1 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .